1. Others
  2. Others

Emixustat hydrochloride (Synonyms: ACU 4429 hydrochloride; ACU-4429 hydrochloride; ACU4429 hydrochloride)

Cat. No.: HY-19720A Purity: 99.50%
Data Sheet SDS Handling Instructions

Emixustat hydrochloride strongly inhibits 11-cis-retinol production with IC50 values of 232 ± 3 nM.

For research use only. We do not sell to patients.
Emixustat hydrochloride Chemical Structure

Emixustat hydrochloride Chemical Structure

CAS No. : 1141934-97-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO $181 In-stock
2 mg $110 In-stock
5 mg $200 In-stock
10 mg $320 In-stock
50 mg $1100 In-stock
100 mg $1750 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Emixustat hydrochloride:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Emixustat hydrochloride strongly inhibits 11-cis-retinol production with IC50 values of 232 ± 3 nM. IC50 value: 232 nM [1] Target: 11-cis-retinol Emixustat hydrochloride is a novel visual cycle modulator, in healthy volunteers. Oral Emixustat was safe and well tolerated when administered once daily for 14 days with minimal systemic adverse events reported. Evaluation of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration.[2]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01002950 Acucela Inc.|Otsuka Pharmaceutical Co., Ltd. Dry Age-related Macular Degeneration|Geographic Atrophy October 2009 Phase 2
NCT00942240 Acucela Inc.|Otsuka Pharmaceutical Co., Ltd. Healthy July 2009 Phase 1
NCT00703183 Acucela Inc. Healthy May 2008 Phase 1
NCT01802866 Acucela Inc.|Otsuka Pharmaceutical Co., Ltd. Geographic Atrophy February 2013 Phase 2|Phase 3
NCT01002950 Acucela Inc.|Otsuka Pharmaceutical Co., Ltd. Dry Age-related Macular Degeneration|Geographic Atrophy October 2009 Phase 2
NCT00942240 Acucela Inc.|Otsuka Pharmaceutical Co., Ltd. Healthy July 2009 Phase 1
NCT00703183 Acucela Inc. Healthy May 2008 Phase 1
NCT01802866 Acucela Inc.|Otsuka Pharmaceutical Co., Ltd. Geographic Atrophy February 2013 Phase 2|Phase 3
NCT03033108 Acucela Inc. Stargardt Disease January 2017 Phase 2
NCT02753400 Acucela Inc. Proliferative Diabetic Retinopathy April 2016 Phase 2
NCT02130531 Acucela Inc. Geographic Atrophy|Age-Related Macular Degeneration April 2014 Phase 1
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 3.3351 mL 16.6756 mL 33.3511 mL
5 mM 0.6670 mL 3.3351 mL 6.6702 mL
10 mM 0.3335 mL 1.6676 mL 3.3351 mL
References
M.Wt

299.84

Formula

C₁₆H₂₆ClNO₂

CAS No.

1141934-97-5

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 44 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Emixustat hydrochloride
Cat. No.:
HY-19720A
Quantity: